141 results
DEF 14C
ATXI
Avenue Therapeutics Inc
18 Mar 24
Information statement
4:59pm
Statement is furnished solely for the purpose of advising stockholders of the actions taken by written consent and giving stockholders advance notice … and unissued shares may be issued for cash, to acquire property or for any other purpose that is deemed in the best interests of our company. Any decision
PRE 14C
ATXI
Avenue Therapeutics Inc
8 Mar 24
Preliminary information
4:31pm
for the purpose of advising stockholders of the actions taken by written consent and giving stockholders advance notice of the actions taken.
FORWARD-LOOKING … , to acquire property or for any other purpose that is deemed in the best interests of our company. Any decision to issue additional shares will reduce
424B3
ghegr
2 Feb 24
Prospectus supplement
12:00am
DEF 14C
4pgvl3gca39gja8a rhq
29 Jan 24
Information statement
8:00am
PRE 14C
ma7at8
17 Jan 24
Preliminary information
5:05pm
8-K
EX-4.2
86hde bqp
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.1
ih6de93
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-10.2
omxjc
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-10.1
endd9ao8t0gvyer1s8tc
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-10.1
t72qn5iua8m odlspa
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.2
xgcq1oh
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.1
0lni2bkm
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.4
hlur6ayq1ld
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-10.2
yhao s1t3g0yl83
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm